1. Meaning 

Cannabis genomics governance refers to the legal, regulatory, ethical and institutional framework governing the study, collection, sequencing, modification, storage, commercial use and ownership of the genetic information of cannabis plants (Cannabis sativa L.).

Cannabis genomics can identify genetic variations associated with cannabinoid production, disease resistance, flowering time, plant morphology and other traits. These findings may be used to develop new cultivars, improve agricultural production, support pharmaceutical research and authenticate plant varieties.

Governance becomes legally complex because cannabis is regulated differently across jurisdictions, while its genetic resources may also be subject to intellectual-property rights, biodiversity rules, research restrictions and contractual obligations.

There is no single, universally recognized legal doctrine called “Cannabis Genomics Governance.” It is better understood as an interdisciplinary legal framework assembled from established laws concerning biotechnology, cannabis control, plant variety protection, patents, privacy, biodiversity and research ethics.

NIH to investigate minor cannabinoids and terpenes for potential pain-relieving properties | NCCIH

Plant genetic resources

Governing access to cannabis seeds, breeding lines, landraces, tissue samples and other biological material.

The DNA Revolution: Why Cannabis Genetics are the New Gold Rush | Dr. Green Digital Key

Genomic research and modification

Regulating DNA sequencing, gene editing, research permits, laboratory safety and the use of genetic data.

Developing a public hemp germplasm collection - AgriLife Today

Commercialization and accountability

Addressing patent claims, plant breeders' rights, licensing, benefit sharing, product claims and traceability.

2. Principal legal issues

A. Cannabis cultivation and research authorization

The first question is whether the underlying cannabis activity is lawful. A genomics laboratory cannot assume that authorization to sequence DNA also authorizes it to cultivate, possess, transport, export or distribute the plant.

Depending on the country and the type of cannabis, separate rules may govern:

Cultivation and possession of cannabis plants.

Import and export of seeds, samples and plant material.

Controlled-substance research and laboratory security.

Clinical trials and medicinal-product development.

Sale or distribution of cannabis-derived products.

In the United States, the Controlled Substances Act, the federal hemp definition and applicable state laws may produce different outcomes for different materials and activities. The FDA also distinguishes lawful research from authorization to market a product as a medicine.

FDA+1

Governance principle: genomic research permission, cultivation permission and commercial marketing authorization must be assessed separately.

B. Ownership of cannabis genetic information

A central question is whether a company or researcher can claim exclusive ownership over a cannabis genome, naturally occurring DNA sequence, isolated trait or newly developed cultivar.

The answer depends on what is claimed and the jurisdiction.

A patent does not necessarily confer ownership of every plant carrying a particular sequence, nor does it override controlled-substance or biodiversity laws.

C. Genetic privacy and data governance

Cannabis plant genomic data is not ordinarily personal genetic data merely because it relates to a plant. However, associated records can raise privacy issues when they identify individual breeders, farmers, patients, employees, research participants or Indigenous communities.

A sound governance framework should address:

Lawful collection and permitted purposes.

Consent and confidentiality where required.

Access controls and cybersecurity.

Data retention, sharing and cross-border transfers.

Commercial reuse and publication of research results.

Restrictions on disclosure of confidential breeding material.

Human genetic data generated during cannabis-related medical research may trigger additional health-data and research-participant protections.

3. Cannabis genomics governance under Indian law

For India, the legal framework is particularly important because cannabis cultivation, access to biological resources and intellectual-property protection are governed by different statutes.

A. Narcotic Drugs and Psychotropic Substances Act, 1985

The Narcotic Drugs and Psychotropic Substances Act, 1985 (NDPS Act) regulates cannabis-related activities. Section 8 generally prohibits specified activities involving narcotic drugs and cannabis except as permitted by the Act, rules or applicable authorization.

Section 14 provides a limited exception allowing the Central Government to permit cultivation of cannabis plants exclusively for obtaining fibre or seed, or for horticultural purposes, subject to its conditions.

Consequently, a cannabis-genomics project must assess the plant material, intended purpose, location and applicable permissions. A research objective does not itself create an exemption from the NDPS Act.

India Code

B. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 addresses access to biological resources, research results, intellectual-property applications and benefit sharing. The 2023 Amendment came into force on 1 April 2024.

India Code+1

Its relevance to cannabis genomics includes:

Access to biological resources: Determine whether the cannabis material falls within the Act and whether the researcher or company is subject to approval or intimation requirements.

Research-result transfers: Cross-border transfers and transfers to specified persons may require regulatory scrutiny.

Intellectual property: Section 6 and the amended statutory framework govern relevant intellectual-property applications and commercialization.

Benefit sharing: Commercial exploitation of covered biological resources may trigger fair and equitable benefit-sharing obligations.

Traditional knowledge: Cannabis-related knowledge held by farming or local communities may raise biodiversity, documentation and equitable-benefit concerns.

The precise requirements depend on the applicant's status, the source of the material, the activity, statutory exemptions and the applicable post-amendment rules. The National Biodiversity Authority's official guidance specifically addresses genotyping and the transfer of biological samples abroad.

National Biodiversity Authority+1

C. Patents Act, 1970

Indian patent law creates an important distinction between a patentable technical invention and a biological discovery that the statute excludes.

Relevant provisions include:

Section 3(c): Discoveries of living things or non-living substances occurring in nature are excluded.

Section 3(j): Plants and animals in whole or in part, other than microorganisms, and essentially biological processes for production or propagation are excluded, subject to the statutory wording.

Section 6 of the Biological Diversity Act: Additional requirements may apply to intellectual-property applications involving covered biological resources.

A novel cannabis gene-editing technique, laboratory process, analytical platform or formulation must be assessed against the applicable patentability requirements and exclusions. A naturally occurring cannabinoid profile or genetic sequence is not automatically patentable merely because it has been identified.

D. Protection of Plant Varieties and Farmers' Rights Act, 2001

The Protection of Plant Varieties and Farmers’ Rights Act, 2001 provides a distinct framework for protecting eligible plant varieties and recognizing farmers' rights.

A cannabis breeder would need to examine whether the proposed variety meets the statutory eligibility criteria, whether the crop and application are legally admissible, and whether the relevant variety can be registered under the Act.

Important considerations include:

Novelty, distinctiveness, uniformity and stability, as applicable.

Evidence of breeding history and genetic identity.

Rights associated with propagating material.

Farmers' rights and benefit-sharing provisions.

Interactions between variety protection, patent exclusions and biodiversity requirements.

Plant variety registration should not be assumed to authorize cannabis cultivation otherwise prohibited by applicable drug-control law.

4. Important case laws and their application

The following judgments establish principles relevant to cannabis genomics governance. These are not all cannabis-specific cases. They are precedents concerning genetic material, biotechnology, plant-variety protection and the legal treatment of scientific discoveries.

Case 1: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

569 U.S. 576 (2013) · United States Supreme Court

Facts: Myriad Genetics identified the location and sequence of human BRCA1 and BRCA2 genes and obtained patents covering certain DNA sequences. The patents were challenged because the genetic material occurred naturally.

Judgment: The Supreme Court held that naturally occurring DNA does not become patent-eligible merely because it has been isolated. Complementary DNA (cDNA), however, may be patent-eligible because it is not naturally occurring in the same form.

Justia U.S. Supreme Court Center+1

Application to cannabis genomics:

Merely identifying a naturally occurring cannabis gene or genetic sequence does not necessarily establish a patentable invention.

A genuinely engineered genetic construct or novel technical process may receive different treatment.

Patent eligibility does not automatically establish novelty, inventive step, sufficient disclosure or freedom from other legal restrictions.

Legal principle: Discovery of a natural genetic feature must be distinguished from creation of a qualifying invention.

Case 2: Diamond v. Chakrabarty (1980)

447 U.S. 303 (1980) · United States Supreme Court

Facts: Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down multiple components of crude oil, a property not found in naturally occurring bacteria.

Judgment: The Court held that the artificially created microorganism could qualify as patentable subject matter under the US Patent Act.

LII / Legal Information Institute+1

Application to cannabis genomics: The judgment supports the distinction between naturally occurring cannabis characteristics and certain human-engineered biological inventions. For example, a specifically engineered biological construct may raise different patent questions from a naturally occurring cannabinoid-production pathway.

However, this US judgment does not override India's statutory exclusions for plants and plant parts, nor does it authorize otherwise unlawful cannabis cultivation.

Legal principle: Human-engineered biological inventions may be treated differently from discoveries of nature, subject to the governing patent statute.

Case 3: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

Supreme Court of India · Civil Appeal Nos. 4616–4617 of 2018 and connected matters · Judgment dated 8 January 2019

Facts: The dispute concerned Monsanto's patent claims relating to genetically modified cotton technology, including Bt cotton, and the relationship between patent protection and India's plant-variety legislation.

Judgment: The Supreme Court set aside the Delhi High Court's decision that had effectively invalidated the patent at the interim stage and remanded the matter for consideration on the merits. It did not finally determine every question about the patent's validity.

Sci API+1

Application to cannabis genomics:

A patent relating to a genetic technology and protection for a plant variety are legally distinct questions.

The classification of the claimed invention matters.

The relevant statutory exclusions and the relationship between the Patents Act and the Protection of Plant Varieties and Farmers' Rights Act must be assessed carefully.

Legal principle: Biotechnology patent disputes require attention to the precise claims and the interaction between different intellectual-property statutes.

Case 4: Pioneer Overseas Corporation v. Chairperson, Protection of Plant Varieties and Farmers' Rights Authority (2019)

W.P.(C) 6470/2013 · Delhi High Court · 1 July 2019

Facts: Pioneer Overseas disputed the genetic identity of a maize variety and sought DNA testing after the regulator had declined its request, relying on the variety's successful distinctiveness, uniformity and stability (DUS) testing.

Judgment: The Delhi High Court permitted DNA testing, rejecting the regulator's approach to the request. The decision illustrates that genetic testing may be relevant evidence in plant-variety disputes.

WTO TRIPS Case Law Digest

Application to cannabis genomics:

DNA profiling can assist in assessing whether two claimed varieties are genetically distinguishable.

Genetic evidence may be relevant to infringement, identity, breeding history or competing registration claims.

Laboratory results must be interpreted alongside statutory criteria and other evidence; a DNA profile does not necessarily settle every legal question.

Legal principle: Genomic evidence can play an important role in plant-variety adjudication, subject to the governing legal standard.

Case 5: Funk Brothers Seed Co. v. Kalo Inoculant Co. (1948)

333 U.S. 127 (1948) · United States Supreme Court

Facts: The dispute concerned a mixture of naturally occurring nitrogen-fixing bacterial strains that could be used together without inhibiting one another.

Judgment: The Court rejected the relevant patent claims because the combination did not sufficiently alter the bacteria or create a qualifying invention under the applicable patent law.

Application to cannabis genomics: Simply combining naturally occurring cannabis genetic traits, identifying an existing trait or documenting a naturally occurring cannabinoid profile may not be sufficient for patent protection. The actual technical contribution and the applicable statutory requirements must be examined.

Legal principle: Discovering a useful natural relationship does not necessarily amount to a patentable invention.

5. Comparative analysis of the precedents

The central limitation is that none of these decisions establishes a comprehensive, cannabis-specific genomics code. Their relevance lies in the broader legal principles they provide.

6. Biodiversity, traditional knowledge and benefit sharing

Cannabis genetic resources may have been developed through generations of selection by farmers and communities. Governance therefore involves more than deciding which company can patent an invention.

A responsible framework should consider:

Provenance: Where were the seeds, landraces or tissue samples obtained?

Lawful access: Were applicable permits, approvals and contractual requirements satisfied?

Traditional knowledge: Was relevant community knowledge documented or used?

Equitable benefit sharing: Do applicable laws require financial or non-financial benefits to be shared?

Attribution and confidentiality: Are contributors appropriately recognized and confidential information protected?

Cross-border use: Are sample exports, genomic-data transfers and subsequent commercialization permitted?

Under India's Biological Diversity Act, applicable benefit-sharing and access requirements must be assessed against the particular material, parties, activity and statutory exemptions. Not every cannabis-related genetic dataset automatically attracts identical obligations.

7. Governance of gene editing and genetically modified cannabis

Gene editing raises questions that are distinct from ordinary sequencing or plant breeding.

Potential legal issues include:

Whether the edited organism falls within applicable genetically modified organism regulations.

Whether environmental release or field trials require approval.

Whether the change affects plant-variety eligibility or patentability.

Whether the modified cannabis material remains subject to controlled-substance restrictions.

Whether unintended genetic changes and environmental effects have been assessed.

Who bears responsibility for laboratory errors, unauthorized releases or misleading product claims.

A genome-edited plant is not automatically lawful merely because it contains no foreign DNA. Regulatory classification varies by jurisdiction and by the nature of the modification.

A sound governance regime should therefore require documented risk assessments, appropriate authorization, traceability and post-release monitoring where applicable.

8. Institutional accountability and enforcement

Effective cannabis genomics governance requires coordination among several institutions rather than reliance on a single regulator.

Regulatory oversight

Authorities determine whether cultivation, possession, sample transfers, research and commercialization comply with applicable laws.

Research institutions

Laboratories maintain sample records, validate methods, document consent where applicable and ensure compliance with research protocols.

Breeders and biotechnology companies

Applicants establish ownership or lawful access, document invention claims and comply with licensing and benefit-sharing obligations.

Courts and dispute-resolution bodies

Courts assess patent validity, infringement, contractual disputes, regulatory challenges and the admissibility and weight of genetic evidence.

Potential remedies for non-compliance include regulatory suspension, refusal or cancellation of an intellectual-property right where legally justified, contractual damages, injunctions, penalties and criminal sanctions where the relevant statute provides for them.

9. Hypothetical legal example

Suppose a biotechnology company obtains cannabis seeds from a local farming community, sequences their genomes, identifies a naturally occurring trait associated with cannabinoid production, edits another gene to alter flowering time and seeks exclusive commercial rights.

The legal assessment would involve several independent questions:

Access: Was the original genetic material lawfully obtained?

Biodiversity: Do the access, research, intellectual-property and benefit-sharing provisions of the Biological Diversity Act apply?

Controlled substances: Were the cultivation, possession and laboratory activities authorized under the NDPS Act and relevant rules?

Patentability: Does the proposed claim cover a natural discovery, an eligible technical invention or excluded plant subject matter?

Plant variety rights: Is the resulting cultivar eligible for protection under applicable legislation?

Commercialization: Are cultivation, testing, distribution and product claims legally authorized?

Even if the gene-editing method is patentable, that does not automatically give the company unrestricted rights over the original landrace, exempt it from benefit-sharing requirements or authorize commercial cannabis sales.

10. Recommended principles for a cannabis genomics governance framework

A robust governance model should include the following safeguards:

Legality first: Verify research, cultivation and transfer permissions before beginning the project.

Transparent provenance: Maintain auditable records of genetic material and its source.

Narrow intellectual-property claims: Distinguish natural genetic features from genuine technical inventions.

Community protections: Respect applicable farmers' rights, traditional knowledge and benefit-sharing rules.

Scientific integrity: Validate genomic tests and document uncertainty and limitations.

Data security: Control access to confidential genomic databases and associated personal information.

Biosafety: Apply risk-based review to genetic modification, trials and environmental release.

Accountability: Assign clear responsibility for compliance, recordkeeping, adverse events and corrective action.

Cross-border coordination: Review export controls, sample transfers and destination-country requirements before international collaboration.

Conclusion

Cannabis genomics governance is best understood as a multi-layered framework combining cannabis control, biotechnology regulation, biodiversity protection, plant-variety rights, patent law, privacy and scientific accountability.

The case laws provide complementary principles: Myriad Genetics and Funk Brothers caution against claiming exclusive rights over discoveries of nature; Chakrabarty recognizes that certain engineered biological inventions may be patentable; and the Indian judgments in Monsanto v. Nuziveedu and Pioneer Overseas demonstrate the importance of statutory classification and genetic evidence in plant-related disputes.

For India, the decisive point is that scientific novelty does not by itself establish legal permission. A project must separately satisfy applicable requirements for access to biological resources, cannabis-related activities, intellectual-property protection and commercialization.

This is a general legal analysis for academic and research purposes, not a substitute for jurisdiction-specific advice on a particular cannabis genomics project.